FDA’s new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The Readout
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Wash your lettuce extra thoroughly! There’s never been a better reason to get a salad spinner.
The need-to-know this morning
